质子泵抑制药(PPIs)是临床中主要的抑酸药,奥美拉唑、埃索美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑等PPIs在药动学方面存在很大的差异(如生物利用度、代谢型、药物的相互作用、生物特异性等方面)。近年来,有很多文献报道了P450酶(CYP)代谢对PPIs的药动学影响。临床证据证明PPIs安全有效,但仍有很多患者对PPIs耐药,所以在实践中应该选择性应用PPIs。 Proton pump inhibitors (PPIs) are the major antacids in clinical practice. PPIs such as omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole exist in pharmacokinetics Large differences (such as bioavailability, metabolism, drug interactions, biological specificity, etc.). In recent years, there are many reports on the pharmacokinetic effects of P450 enzyme (CYP) metabolism on PPIs. Clinical evidence that PPIs safe and effective, but there are still many patients resistant to PPIs, so in practice should be selective application of PPIs.